当前位置:上海富雨生物科技有限公司>>细胞库 / 细胞培养>>普通细胞>> SNU-398人肝癌细胞(附S
人肝癌细胞SNU-398
种属 | 人 |
别称 | SNU398; NCI- SNU- 39 8 |
组织来源 | 肝脏 |
疾病 | 肝细胞癌 |
传代比例/细胞消化 | 1:2传代 ,消化1-3分钟 , |
培养基配置 | RPMI1640 培养基: 10%胎牛血清 ; 1%双抗 |
简介 | SNU-398 于 1990 年由 J.-G. Park 及其同事取自一名韩国患者的间变性肝细胞癌 ,该患者已通过脂质体加 和-C 的组合进行了经导管动脉栓塞治疗。既可以附着细胞也可以悬浮细胞。悬浮的细胞是可行的 ,不应丢 弃。通过温和离心 (125 xg) 回收悬浮细胞 ,以与贴壁细胞群一起进行继代培养。 |
形态 | 上皮细胞样 |
生长特征 | 悬浮贴壁生长 |
倍增时间 | 每周 2 至 3 次 |
抗原表达 | Blood Type O; Rh + |
STR | Amelogenin: X,Y CSF1PO: 13 D13S317: 11 D16S539: 10, 14 D5S818: 12 D7S820: 10, 11 THO1: 7,9 TPOX:11 vWA: 17, 18 |
保藏机构 | ATCC; CRL- 2233 |
Background: Hospitals face mounting pressure to reduce unplanned utilization amid rising healthcare demands from an aging population. The Case management for At-Risk patients in the Emergency Department (CARED) program is among the first ED transitional care strategies to focus on both frail older adults and Emergency Department (ED) re-attenders to reduce acute hospital utilization. This study aims to evaluate the effectiveness of the CARED program in reducing hospital (re)admissions and ED re-attendances within 30- and 60-days post-discharge.
Methods: A retrospective, propensity-matched study was conducted from April 2022 to July 2023 in the ED of Ng Teng Fong General Hospital in Singapore. The CARED program identifies and enrols at-risk patients i.e., frail older adults and patients who re-attend the ED within 30 days of hospital discharge, for a geriatric assessment. This is followed by multidisciplinary team care, discharge planning and right siting of care from the ED to community-based services by ED case managers. The primary outcomes were hospital (re)admissions and ED re-attendances within 30- and 60-days post-discharge. Secondary outcomes were cost avoidance and bed occupancy days from reduced acute hospital usage.
untreated host, most aeTSAs are undetected by the immune system. We present evidence suggesting that vaccines inducing direct aeTSA presentation by DCs may represent an attractive strategy for cancer treatment.Checkpoint inhibitors (eg, programmed cell death protein 1 [PD-1], programmed cell death ligand 1 [PD-L1], cytotoxic T-lymphocyte associated protein 4 [CTLA-4] antibodies) are changing how we understand cancer and provide a means to develop modern
请输入账号
请输入密码
请输验证码
以上信息由企业自行提供,信息内容的真实性、准确性和合法性由相关企业负责,化工仪器网对此不承担任何保证责任。
温馨提示:为规避购买风险,建议您在购买产品前务必确认供应商资质及产品质量。